EU Approval of Inavolisib Combo for Breast Cancer and Other Oncology Advancements

Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

An important advancement has been made in the field of oncology with the EU approving a specific drug combo Inavolisib, for a type of breast cancer.

Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma

Advancements have also been made in the management of immune-checkpoint inhibitor toxicities in Melanoma.

FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma

Another breakthrough is the FDA’s fast track designation to SRN-101 for the treatment of high-grade Glioma.

Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma

Significantly, a new small molecule showcasing promising early activity in treating multiple myeloma, indicating a potential new direction in treatment approaches for this form of cancer.

Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC

On quality of life in cancer treatment, a comparison of outcomes with different treatments for a specific cancer has been discussed.

3 Things You Should Know About PSMA-Directed Imaging and Radioligand Therapy in Prostate Cancer

To conclude, essential information is offered about PSMA-Directed Imaging and radioligand therapy, a specific method used in treating prostate cancer.

More From Author

Scientific Innovations in Plant-based Foods and Antimicrobial Resistance – Exploring Potential Health Benefits

FDA Recognitions and Updates on Oncology Treatments

Leave a Reply

Your email address will not be published. Required fields are marked *